Pay in 4 interest-free payments of $45.00 Learn more
Ships within 48 hours · Estimated delivery Jul 26 - Jul 31
2817-2822 (2004)
Chemical Name: 2-(2-Chloro-4-iodophenylamino)-N-(cyclopropylmethoxy)-3
CN1C2=CC=C(C=C2N=C1CCCC(O)=O)N(CCCl)CCCl
GSK-1292263 is a novel GPR119 agonist that is currently under development for the treatment of type 2 diabetes
3-[18-(2-carboxyethyl)-8
THIQ rafenib D3) 2817-2822 (2004)THIQ is the first selective agonist of the melanocortin 4 receptor (MC4R), with high affinity and potency for hMC4R (IC50=1. 2 nM, EC50=2. 1 nM) and rMC4R (IC50=0. 6 nM, EC50=2. 9 nM). THIQ maintains low potency at MC1R, MC3R and MC5R. THIQ plays a role in eliciting erectile activity in rodents. THIQ acts as a pharmacoperone of the MC4R rescuing the cell surface expression and signaling of some intracellularly retained MC4R mutants. Product